PRAN 2.56..bottom yet? no position yet..waiting 2.22 jic,lol

losers..http://finviz.com/screener.ashx?v=210&s=ta_toplosers

HCI done consolidating at 36? Sucker needs to get back to 40..has had bounce fart to 38/39s since big drop but hasn't been able to break free

ISRG back to 500+..$65 move..gotta luv davinci

EXEL trying to stop sucking..holding small ..looking for partial recovery back to 4.50-5

Still holding a chunk of BODY..might be a mistake not taking all off yesterday over 1.10..but think pos can do better..maybe 1.50

Works for me..some yesterday .1666 and out .22..not many thou since Q is highly likely..lunch money..lol

GM Z

Dyslexic non-alive cat bounce?

CWTR dead cat bounce off yesterdays Q rumors/articles

Lolzzz..time for some Chianti and fava beans?

GM ARTX quite the fade, watching MDCO..might be interesting

Clean Energy Fuels opens two more LNG fueling stations, shares +10.7%
Clean Energy Fuels (CLNE) +10.7% premarket on news it has opened two more America's Natural Gas Highway stations, one in Texas and one in Oklahoma, to serve UPS' growing heavy-duty truck fleet that runs of liquefied natural gas.
Additional truck fueling agreements were announced for fleets fueling across CLNE's nationwide network from Los Angeles to Jacksonville, Fla

Judge affirms patent on Eli Lilly lung-cancer drug
A district judge has upheld the validity of a patent on Eli Lilly's (LLY) blockbuster Alimta lung-cancer drug, which generates sales of $2.6B a year.
The decision will maintain the treatment's exclusivity until 2022, pending the outcome of any appeal.
Companies on the losing side in the case include Teva (TEVA) and Fresenius Kabi (APCVZ).
http://seekingalpha.com/pr/9427913-u-s-district-court-upholds-validity-of-lillys-alimta-patent-through-2022

Obamacare Web site goes down twice amid last-minute rush
The government's HealthCare.gov received over 4.8M visitors yesterday while the telephone center took 2M calls as people rushed to sign up for Obamacare health coverage ahead of last night's deadline.
However, the enrollment process was again mired in chaos, as the Web site went down at least twice and was out for several hours.
Those who started the enrollment process but didn't complete it will be allowed to do so, providing more uncertainty for health insurers.
With 6M people having bought coverage by last week, the government could reach its target of signing up 7M people by around this point in the process.
However, an estimated 45M Americans still remain uncovered.
More on Obamacare
Health insurers: AET, HNT, HUM, UNH, WLP, MOH
ETFs: XLV, XHE, VHT, FXH, IHF, IHI, IYH, PTH, RYH, PSCH, RXL, RXD, XHS

ISRG $43 rip p/m..MDCO suckage -15%

Tech ratings changes: Sina, ExOne, Vipshop, MercadoLibre
Sina (SINA +3%) has been upgraded to Outperform by both Pac Crest and UBS.
ExOne (XONE +3.9%) has been upgraded to Buy by BB&T. Shares tumbled 11 days ago due to a Q4 miss and soft guidance.
Vipshop (VIPS +7.3%) has been upgraded to Buy by Goldman. Shares have corrected lately after skyrocketing in response to the company's blowout Q4 numbers and strong guidance.
MercadoLibre (MELI -1.1%) has been started at Sell by Citi. Forex-related concerns have been running high for a while.

Alibaba invests $692M in Chinese department store owner
Alibaba (ABABA) is buying $214M worth of shares in Chinese retailer Intime (INTIF), and $478M worth of convertible bonds. Once the bonds are converted into equity in three years, Alibaba will have a 26.1% stake.
As part of the deal, Alibaba and Intime will create an 80/20 JV focused on converting online activity (inc. smartphone activity) into offline purchases in places such as shopping malls, department stores, and supermarkets.
The deal follows Tencent's $214.7M investment in top Alibaba rival JD.com (set to go public), and is the latest in a string of high-profile investments by the Chinese e-commerce giant. Others:ChinaVision Media, Tango.
Intime investors apparently feel they got a raw deal: Shares fell 7.8% overnight in Hong Kong.

GM Denny +SSS..Premarket Gainers / Losers
Gainers: BIOF +40%. CLNT +35%. MNGA +15%. CRIS +12%. APPY +11%. OXBT +11%. HALO +10%. CREG +9%. GIG +8%. SYN +8%. ARTX +6%. CYTR +6%. VIPS +5%.
Losers: PRAN -67%. WHX -15%. CDTI -12%. MNKD -7%.

MannKind down premarket as Ad Comm prepares to discuss AFREZZA
Shares of MannKind Corp. (MNKD) are down 4% on modest premarket volume.
The Endocrinologic and Metabolic Drugs Advisory Committee reviews AFREZZA's NDA tomorrow.

Lululemon tapped for more gains by Wedbush
Wedbush Securities backs Lululemon (LULU) with a reiterated Outperform rating.
The retailer's new &Go brand has drawn solid reviews for design and early reports are that it's selling well.
LULU +2.3% premarket

ING up 4% as dividend promised next year
“We are on track to become a pure bank,” says new CEO Ralph Hamers. “We have strong financials and a strong track record to deliver what we promise." Dividends will begin after its government bailout is repaid in full, says ING, which should happen by May 2015 at the latest.
ING has paid back more than €12.5B in aid, interest, and premium to the Netherlands, including a €1.23B check today. Still owed is €1.03B which must be returned by May 2015. Owners haven't received a dividend since a €0.74 payout in August 2008.
Shares +3.9% premarket

Curis may proceed with CUDC-427 trial
The FDA completes its review of Curis' (CRIS) CRL response to the partial clinical hold on its anti-cancer agent CUDC-427. The agency determines that it is safe to proceed.
The phase 1 study on patients with solid tumors was placed on partial clinical hold in November after one patient died due to liver failure one month after discontinuing the drug. No new patients could be enrolled until Curis submitted data and analyses on all treated patients plus a protocol amendment.
Shares are up 17% premarket on light volume.

Analysis: Nice entry point for Lions Gate
The pullback in the share price of Lions Gate (LGF) is unwarranted, says JPMorgan.
The investment firm notes the box office sales for Divergent are still tracking in-line with expectations and demand has been strong enough to set up the franchise for profitable sequels.
LGF at current levels is a "great entry point" for investors, says JP.

Energous continues post-IPO tear; shares +24.4% premarket
Energous (WATT), which began trading on Friday, is now up 119% from its $6 IPO price.
The company's market cap is still only at $116M. Its offering arguably bore a stronger resemblance to a Series A VC round than a regular tech IPO: Energous sold a 45% stake at a $53M valuation, and still doesn't have any revenue.
Over the weekend, SA author Real Assets Investment Research noted Energous is banking on a partnership with South Korean electronics OEM Hanbit (has made a $1M investment), imagines licensing its wireless charging tech for use in routers, chips, battery packs, and phones, and hopes to make it available to North American consumers by 2015.

Halozyme's Hylenex meet's main goal of study
Halozyme Therapeutics' (HALO) Hylenex treatment met the main goal of a trial in which a recombinant and a new formulation of the therapy were assessed.
The study compared the use of Hylenex as a pretreatment for Type I diabetes patients receiving insulin injections compared with subjects who didn't receive pre-treatment.
Hylenex achieved non-inferiority of hemoglobin A1C levels at six months, the primary endpoint. A1C indicates how much sugar is in the blood.
Hylenex also reduced rates of hypoglycemia (low blood sugar), which the lead investigator of the study says is a key unmet need.
Shares are +9%
http://seekingalpha.com/pr/9413123-halozyme-announces-that-consistent-1-trial-of-hylenex-recombinant-met-primary-endpoint

FDA confirms lifting of clinical hold on Oxygen Bio's Oxycyte
Oxygen Biotherapeutics (OXBT) has received written confirmation that the FDA has lifted a hold on the clinical trials of the company's Oxycyte treatment for traumatic brain injury.
The FDA had informed Oxygen Bio of its decision verbally earlier this month.
Oxygen has been enrolling patients in Israel for a Phase IIb study to evaluate the safety and tolerability of Oxycyte in patients with severe non-penetrating traumatic brain injury.
Shares jump 10.6% premarket
http://seekingalpha.com/pr/9414453-oxygen-biotherapeutics-inc-provides-an-update-on-communication-with-the-fda-regarding-oxycyte-development-program

Glaxo pulls plug on expanded use of Votrient
After additional analysis of Phase 3 trial data, GlaxoSmithKline (GSK) decides to withdraw its European application for the use of Votrient (pazopanib) in advanced ovarian cancer.
Although initial results showed an improvement in progression-free survival, further analysis failed to show a sufficient benefit-to-risk ratio to proceed.
http://www.reuters.com/article/2014/03/31/us-glaxosmithkline-brief-idUSBREA2U0PB20140331

BODY unPOSing a bit

Add 3.63s EXEL today and .90 BODY yesterday..suckers need to stop sucking..

EXEL,BODY sucked bigly yesterday, added $4 and $1

Ad comm meeting approaches for Durata drug
Anti-Infective Drugs Advisory Committee meets on Monday to review Durata Therapeutics' (DRTX) antibacterial Dalvance (dalbavancin) NDA.
PDUFA date is May 26.
Consensus total revenue estimates for 2014 and 2015 are $16.3M and $67.2M, respectively.
briefing docs..http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/ucm385739.htm

Mylan wins $106.7M in damages in lawsuit against GSK
A jury has ordered GSK (GSK) to pay Mylan (MYL) $106.7M in damages in a breach-of-contract lawsuit related to antidepressant Paroxetine Hydrochloride Extended-Release Tablets.
Mylan says it "intends to seek additional relief to further protect its rights."

Alimera resubmits NDA
Alimera Sciences (ALIM) resubmits its NDA for ILUVIEN after receiving a CRL from the regulator in October.
The product is approved for sale in the UK, Portugal, France, Germany and Spain, but is commercially available only in the UK and Germany.
Consensus revenue estimates for 2014 and 2015 are $13.7M and $36.2M, respectively.
73 mutual funds have positions, up from 23 a year earlier.

Exact Sciences halted ahead of FDA panel meeting for Cologuard
Exact Sciences' (EXAS) shares have been halted ahead of a meeting of an FDA committee to discuss the company's premarket approval application for its Cologuard screening test for colorectal cancer.
The panel is due to start the meeting at 8 am ET.
Trial results showed that compared with colonoscopy, the test is 92% sensitive for cancer stages I and II, and 69% for precancerous polyps containing high-grade dysplasia (highest cancer risk).

Clovis up 10% premarket on positive trial data
Phase 1 results for Clovis Oncology's (CLVS) EGFR inhibitor CO-1686 show a 64% objective response rate in non-small cell lung cancer patients with the T790M mutation.
Median duration of response is undetermined, but progression-free survival greater than six months has been observed in evaluable heavily-pretreated patients with the T790M mutation.
The drug was well-tolerated in 61 of 62 patients.
The company expects to submit an NDA for CO-1686 in 2015.
202 mutual funds have positions, up from 127 a year earlier.
http://seekingalpha.com/pr/9386983-clovis-oncology-s-cominus-1686-demonstrates-compelling-clinical-activity-and-progression-free-survival-pfs-in-updated-phase-1-study-results-in-patients-with-non-small-cell-lung-cancer-nsclc

Baxter to split into two; shares soar
Baxter International (BAX) is splitting into two companies, with one focused on biopharmaceuticals and the other on medical products.
Baxter will make a tax-free distribution of shares in the biopharmaceuticals business to its shareholders. The company expects to complete the transaction by mid-2015.
The biopharmaceuticals business generated 2013 annual revenues of $6B and develops treatments for hemophilia and other bleeding disorders, immune deficiencies, burns and shock.
The medical-products business earned annual sales of over $9B and provides intravenous (IV) solutions and nutritional therapies, drug-delivery systems and administration sets, and premixed and other injectable drugs, as well as inhalation anesthetics and hospital-based biosurgery products.
Baxter CEO Robert Parkinson will head the medical-products company, which will retain the Baxter International name.
Ludwig Hantson, who is president of BioScience, will run the biopharmaceuticals firm.
Shares are +12.5%.

GM Z, how goes the chateau hunt?

in some EXEL 4.44 for shiggles, BODY 1.25 starter cause oversold like a mofo, GGS going Q so tiny .1313 mockingbird lane for fun

weeeeeeeeeeeeeee.. out +$4 on measly 200,lol

INSM superb bounce.. from 12 to 17+